Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIDIUM: QVM149 vs QMF149 in Asthma
NCT02571777Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Primary completion
- Jun 2019
- Modality
- Orthosteric Ligands
- Countries
- 41
01
Overview
Phase 3, randomised, double-blind trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma (5 arms), sponsored by Novartis. Primary endpoint: Trough Forced Expiratory Volume in 1 Second at 26 weeks. Started Dec 2015; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02571777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571777.